Stratagene Corp. (STGN)

Last Trade:	5.48
Trade Time:	3:47PM ET
Change:	1.17 (27.15%)

Stratagene Corporation, a developer, manufacturer and marketer of specialized life science research and diagnostic products, today highlighted the U.S. Food and Drug Administration's (FDA) publication of results from its MicroArray Quality Control (MAQC) project.

As part of the FDA's Critical Path Initiative, the MAQC project aimed to develop standards and quality measures for the microarray community, so that microarrays, as a core technology of pharmacogenomics and toxicogenomics, could successfully and reliably be used in clinical practice and regulatory decision-making. As a result, the MAQC project will help improve microarray technology and foster its proper applications in the discovery, development and review of FDA regulated products.

"We are proud to have been a part of this collaboration that brought together a broad range of academic, governmental, and commercial organizations, all with the future of microarray technology in mind," said Joseph A. Sorge, MD, President and CEO of Stratagene. "Stratagene's Universal Reference RNA was one of two high-quality reference standards selected as part of the MAQC project. These reference RNAs allow laboratories with many different microarray platforms to compare and share data in the global microarray community."

The project involved six FDA Centers, major providers of microarray platforms and RNA samples, the U.S Environmental Protection Agency, the National Institute of Standards and Technology, academic laboratories, and other stakeholders. By providing the public with large reference datasets along with readily accessible reference RNA samples, the MAQC project aimed to establish quality control metrics and thresholds for objectively assessing the performance achievable by various microarray platforms and evaluating the advantages and disadvantages of various data analysis methods.

-----------------------------------------------------------------------------------------------

Arena Pharmaceuticals (ARNA) announced on Tuesday that the company is enrolling patients in trials involving its proposed obesity drug Lorcaserin. The trial is one of three phase III studies evaluating the safety and efficacy of the drug.